• About Us
    • Our Company
    • Management Team
    • Board of Directors
    • Clinical Advisory Board
  • Product Candidates
  • Recent News
    • Press Releases
    • Research + Whitepapers
    • News
  • Contact Us
First-in-class topical therapeutic omilancor ameliorates disease severity and inflammation through activation of LANCL2 pathway in psoriasis

First-in-class topical therapeutic omilancor ameliorates disease severity and inflammation through activation of LANCL2 pathway in psoriasis

by NImmune Biopharma | May 2, 2023 | Research and White Papers

Psoriasis (PsO) is a complex immune-mediated disease that afflicts 100 million people. Omilancor is a locally-acting, small molecule that selectively activates the Lanthionine Synthetase C-like 2 (LANCL2) pathway, resulting in immunoregulatory effects at the...
Next Entries »

Recent Posts

  • NImmune Biopharma Presented New Data at ACG 2026 Supporting the Efficacy and Safety of Innovative LANCL2 Medicines Targeting a Novel Mechanism in Hard-to-Treat IBD
  • NImmune Biopharma Announces Presentations at ACG 2026 Supporting Efficacy of Oral, Once-Daily NIM-1324 LANCL2 Medicine for Hard-to-Treat IBD
  • NImmune Biopharma Announces Presentations at Digestive Disease Week 2026 Supporting a Differentiated Profile and Superior Efficacy of Oral, Once-Daily NIM-1324 for IBD
  • New Data Presented at IMMUNOLOGY2026 Shows LANCL2 Medicines in Clinical Development for IBD Can Provide Protection from Asthma
  • NImmune Biopharma to Present Novel Mechanistic, Efficacy and Translational Data on LANCL2-Targeting Therapeutics Supporting Significant Pipeline-in-a-Drug Potential at IMMUNOLOGY2026

Recent Comments

No comments to show.
  • About Us
  • Management Team
  • Board of Directors
  • Clinical Advisory Board
  • Product Candidates
  • Contact Us

Copyright © 2025 NImmune Biopharma